HTR2A and arteriosclerosis obliterans: Sarpogrelate, a selective 5-HT2 receptor antagonist, is used in patients with arteriosclerosis obliterans to improve ischemic symptoms such as ulcer, pain and coldness of the extremities relate to chronic arterial occlusion17, 29.